Prevention of Contrast-Induced Nephropathy: An Overview

Radiologic Clinics of North America

Volumn 47, Issue 5, 2009, Pages 801-811

  Ellis, James H ^a   Cohan, Richard H ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Contrast induced nephropathy; Iodinated contrast material; Nephropathy; Nephrotoxicity; Prevention; Renal function

Indexed keywords

ACETYLCYSTEINE; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARBON DIOXIDE; CORLOPRAM; CREATININE; DOPAMINE; FENOLDOPAM MESILATE; FUROSEMIDE; GADOLINIUM; IODINATED CONTRAST MEDIUM; IODIXANOL; IOHEXOL; IOPAMIDOL; IOPROMIDE; MANNITOL; MEGLUMINE IOXAGLATE PLUS SODIUM IOXAGLATE; NIFEDIPINE; NITRENDIPINE; PLACEBO; PROBUCOL; PROSTAGLANDIN E1; THEOPHYLLINE; UNCLASSIFIED DRUG;

CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DIAGNOSTIC IMAGING; DRUG EFFICACY; HEMODIALYSIS; HEMOFILTRATION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

ACETYLCYSTEINE; CONTRAST MEDIA; CREATININE; FLUID THERAPY; HEMOFILTRATION; HUMANS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; PREMEDICATION;

EID: 69649092592     PISSN: 00338389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rcl.2009.06.003     Document Type: Review

References (82)

1. Barrett B.J., and Carlisle E.J. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. Radiology 188 1 (1993) 171-178 {A}
2. Rudnick M.R., Goldfarb S., Wexler L., et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. Kidney Int 47 1 (1995) 254-261 {A}
3. Rao Q.A., and Newhouse J.H. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology 239 2 (2006) 392-397 {B}
4. Newhouse J.H., Kho D., Rao Q.A., et al. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. AJR Am J Roentgenol 191 2 (2008) 376-382 {B}
5. Baumgarten D.A., and Ellis J.H. Contrast-induced nephropathy: contrast material not required?. AJR Am J Roentgenol 191 2 (2008) 383-386
6. From A.M., Bartholmai B.J., Williams A.W., et al. Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at Mayo Clinic. Clin J Am Soc Nephrol 3 1 (2008) 10-18 {B}
7. Brown J.R., Malenka D.J., DeVries J.T., et al. Transient and persistent renal dysfunction are predictors of survival after percutaneous coronary intervention: insights from the Dartmouth Dynamic Registry. Catheter Cardiovasc Interv 72 3 (2008) 347-354 {B}
8. Levy E.M., Viscoli C.M., and Horwitz R.I. The effect of acute renal failure on mortality. A cohort analysis. JAMA 275 19 (1996) 1489-1494 {B}
9. Marenzi G., Assanelli E., Marana I., et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 354 26 (2006) 2773-2782 {A}
10. Miner S.E.S., Dzavik V., Nguyen-Ho P., et al. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up. Am Heart J 148 4 (2004) 690-695 {A}
11. Pfister S.A., Deckart A., Laschke S., et al. Unenhanced helical computed tomography vs intravenous urography in patients with acute flank pain: accuracy and economic impact in a randomized prospective trial. Eur Radiol 13 11 (2003) 2513-2520 {A}
12. Committee on Drugs and Contrast Media. Manual on contrast media, version 6. Available at:. http://acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx Accessed January 4, 2009
13. Brink J.A. Contrast optimization and scan timing for single and multidetector-row computed tomography. J Comput Assist Tomogr 27 Suppl 1 (2003) S3-S8
14. Ichikawa T., Erturk S.M., and Araki T. Multiphasic contrast-enhanced multidetector-row CT of liver: contrast-enhancement theory and practical scan protocol with a combination of fixed injection duration and patients' body-weight-tailored dose of contrast material. Eur J Radiol 58 2 (2006) 165-176
15. Hahn S.T., Pfammatter T., and Cho K.J. Carbon dioxide gas as a venous contrast agent to guide upper-arm insertion of central venous catheters. Cardiovasc Intervent Radiol 18 3 (1995) 146-149
16. Kim H., Tsai J., and Paxton B. Safety and utility of uterine artery embolization with CO2 and a gadolinium-based contrast medium. J Vasc Interv Radiol 18 8 (2007) 1021-1027
17. Dewald C.L., Jensen C.C., Park Y.H., et al. Vena cavography with CO2 versus with iodinated contrast material for inferior vena cava filter placement: a prospective evaluation. Radiology 216 3 (2000) 752-757 {A}
18. Liss P., Eklof H., Hellberg O., et al. Renal effects of CO2 and iodinated contrast media in patients undergoing renovascular intervention: a prospective, randomized study. J Vasc Interv Radiol 16 1 (2005) 57-65 {A}
19. Spinosa D.J., Angle J.F., Hagspiel K.D., et al. Lower extremity arteriography with use of iodinated contrast material or gadodiamide to supplement CO2 angiography in patients with renal insufficiency. J Vasc Interv Radiol 11 1 (2000) 35-43
20. Thomsen H.S., Almèn T., Morcos S.K., et al. Gadolinium-containing contrast media for radiographic examinations: a position paper. Eur Radiol 12 10 (2002) 2600-2605
21. Ellis J.H., Cohan R.H., Sonnad S.S., et al. Selective use of radiographic low-osmolality contrast media in the 1990s. Radiology 200 2 (1996) 297-311
22. McCullough P.A., Bertrand M.E., Brinker J.A., et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 48 4 (2006) 692-699 {A}
23. Toutant C. GE unit ordered to pay $11.3 million over false-advertising claims against competitor; judge denies competitor's request that GE subsidiary Amersham disgorge $1 billion in profits. Available at:. http://www.law.com/jsp/article.jsp?id=1202429880602 Accessed April 26, 2009
24. Heinrich M.C., Häberle L., Müller V., et al. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology 250 1 (2009) 68-86 {A}
25. Solomon R.J., Natarajan M.K., Doucet S., et al. Cardiac angiography in renally impaired patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 115 (2007) 3189-3196 {A}
26. Thomsen H.S. Current evidence on prevention and management of contrast-induced nephropathy. Eur Radiol 17 Suppl 6 (2007) F33-F37
27. Mueller C., Buerkle G., Buettner H.J., et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 162 3 (2002) 329-336 {A}
28. Weisbord S.D., and Palevsky P.M. Prevention of contrast-induced nephropathy with volume expansion. Clin J Am Soc Nephrol 3 1 (2008) 273-280
29. Jakobsen J.A., Berg K.J., Waaler A., et al. Renal effects of the non-ionic contrast medium iopentol after intravenous injection in healthy volunteers. Acta Radiol 31 1 (1990) 87-91 {B}
30. Merten G.J., Burgess W.P., Gray L.V., et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291 19 (2004) 2328-2334 {A}
31. Adolph E., Holdt-Lehmann B., Chatterjee T., et al. Renal insufficiency following radiocontrast exposure trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy. Coron Artery Dis 19 6 (2008) 413-419 {A}
32. Navaneethan S.D., Singh S., Appasamy S., et al. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis 53 4 (2009) 617-627 {A}
33. Ho K.M., and Morgan D.J. Use of isotonic sodium bicarbonate to prevent radiocontrast nephropathy in patients with mild pre-existing renal impairment: a meta-analysis. Anaesth Intensive Care 36 5 (2008) 646-653 {A}
34. Hogan S.E., L'Allier P., Chetcuti S., et al. Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis. Am Heart J 156 3 (2008) 414-421 {A}
35. Solomon R., Werner C., Mann D., et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331 21 (1994) 1416-1420 {A}
36. Dussol B., Morange S., Loundoun A., et al. A randomized trial of saline hydration to prevent contrast nephropathy in chronic renal failure patients. Nephrol Dial Transplant 21 8 (2006) 2120-2126 {A}
37. Madyoon H., Croushore L., Weaver D., et al. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interv 53 3 (2001) 341-345 {B}
38. Allaqaband S., Tumuluri R., Malik A.M., et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 57 3 (2002) 279-283 {A}
39. Tumlin J.A., Wang A., Murray P.T., et al. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 143 5 (2002) 894-903 {A}
40. Stone G.W., McCullough P.A., Tumlin J.A., et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 290 17 (2003) 2284-2291 {A}
41. Tepel M., van der Giet M., Schwarzfeld C., et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343 3 (2000) 180-184 {A}
42. Kelly A.M., Dwamena B., Cronin P., et al. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 148 4 (2008) 284-294 {A}
43. Bagshaw S.M., McAlister F.A., Manns B.J., et al. Acetylcysteine in the prevention of contrast-induced nephropathy. A case study of the pitfalls in the evolution of evidence. Arch Intern Med 166 2 (2006) 161-166
44. Biondi-Zoccai G.G.L., Lotrionte M., Abbate A., et al. Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. BMJ 332 7535 (2006) 202-209
45. Vaitkus P.T., and Brar C. N-acetylcysteine in the prevention of contrast-induced nephropathy: publication bias perpetuated by meta-analyses. Am Heart J 153 2 (2007) 275-280
46. Van Praet J.T., and De Vriese A.S. Prevention of contrast-induced nephropathy: a critical review. Curr Opin Nephrol Hypertens 16 4 (2007) 336-347
47. Hoffmann U., Fischereder M., Krüger B., et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 15 2 (2004) 407-410 {B}
48. Diskin C.J. Creatinine and glomerular filtration rate: evolution of an accommodation. Ann Clin Biochem 44 1 (2007) 16-19
49. Preiss D.J., Godber I.M., Lamb E.J., et al. The influence of a cooked-meat meal on estimated glomerular filtration rate. Ann Clin Biochem 44 Pt 1 (2007) 35-42 {B}
50. Poletti P.A., Saudan P., Platon A., et al. IV N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol 189 3 (2007) 687-692 {A}
51. Rehman T., Fought J., and Solomon R. N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients. Clin J Am Soc Nephrol 3 (2008) 1610-1614 {B}
52. Fishbane S., Durhan J.H., Marzo K., et al. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. J Am Soc Nephrol 15 (2004) 251-260
53. Shalansky S.J., Vu T., Pate G.E., et al. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best?. Pharmacotherapy 25 8 (2005) 1095-1103
54. Huber W., Eckel F., Hennig M., et al. Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology 239 3 (2006) 793-804 {B}
55. Ix J.H., McCulloch C.E., and Chertow G.M. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant 19 11 (2004) 2747-2753 {A}
56. Bagshaw S.M., and Ghali W.A. Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch Intern Med 165 10 (2005) 1087-1093 {A}
57. Weinstein J.M., Heyman S., and Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 62 4 (1992) 413-415 {A}
58. Li G., Yin L., Liu T., et al. Role of probucol in preventing contrast-induced acute kidney injury after coronary interventional procedure. Am J Cardiol 103 4 (2009) 512-514 {A}
59. Boscheri A., Weinbrenner C., Botzek B., et al. Failure of ascorbic acid to prevent contrast-media induced nephropathy in patients with renal dysfunction. Clin Nephrol 68 5 (2007) 279-286 {A}
60. Morikawa S., Sone T., Tsuboi H., et al. Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol 53 12 (2009) 1040-1046 {A}
61. Gupta R.K., Kapoor A., Tewari S., et al. Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomized study. Indian Heart J 51 5 (1999) 521-526 {A}
62. Khoury Z., Schlicht J.R., Como J., et al. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy 15 1 (1995) 59-65 {A}
63. Madsen J.K., Jensen W., Sandermann J., et al. Effect of nitrendipine on renal function and on hormonal parameters after intravascular iopromide. Acta Radiol 39 4 (1998) 375-380 {A}
64. 1: a randomized, double-blind, placebo-controlled. Am J Ther 8 3 (2001) 155-162 {A}
65. Koch J.-A., Plum J., Grabensee B., et al. Prostaglandin E1: a new agent for the prevention of renal dysfunction in high risk patients caused by radiocontrast media? PGE1 Study Group. Nephrol Dial Transplant 15 1 (2000) 43-49 {A}
66. Morcos S.K. Prevention of contrast media nephrotoxicity - the story so far. Clin Radiol 59 5 (2004) 381-389
67. Morcos S.K. Prevention of contrast media-induced nephrotoxicity after angiographic procedures. J Vasc Interv Radiol 16 1 (2005) 13-23
68. Pannu N., Wiebe N., Tonelli M., et al. Prophylaxis strategies for contrast-induced nephropathy. JAMA 295 23 (2006) 2765-2779
69. Stacul F., Adam A., Becker C.R., et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 98 Suppl (2006) 59k-77k
70. Thomsen H.S., Morcos S.K., and Barrett B.J. Contrast-induced nephropathy: the wheel has turned 360 degrees. Acta Radiol 49 6 (2008) 646-657
71. Sterling K.A., Tehrani T., and Rudnick M.R. Clinical significance and preventive strategies for contrast induced nephropathy. Curr Opin Nephrol Hypertens 17 6 (2008) 616-623
72. Cruz D.N., Perazella M.A., Bellomo R., et al. Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Kidney Dis 48 3 (2006) 361-371 {A}
73. Vogt B., Ferrari P., Schönholzer C., et al. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med 111 9 (2001) 692-698 {A}
74. Lehnert T., Keller E., Gondolf K., et al. Effect of haemodialysis after contrast medium administration in patients with renal insufficiency. Nephrol Dial Transplant 13 2 (1998) 358-362 {A}
75. Marenzi G., Lauri G., Campodonico J., et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 119 2 (2005) 155-162 {A}
76. Marenzi G., Marana I., Lauri G., et al. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. N Engl J Med 349 14 (2003) 1333-1340 {A}
77. Elicker B.M., Cypel Y.S., and Weinreb J.C. IV contrast administration for CT: a survey of practices for the screening and prevention of contrast nephropathy. AJR Am J Roentgenol 186 6 (2006) 1651-1658
78. Thomsen H.S., and Morcos S.K. Risk of contrast-medium-induced nephropathy in high risk patients undergoing MDCT - a pooled analysis of two randomized trials. Eur Radiol 19 4 (2009) 891-897 {A}
79. Barrett B.J., Katzberg R.W., Thomsen H.S., et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol 41 11 (2006) 815-821 {A}
80. Thomsen H.S., Morcos S.K., Erley C.M., et al. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol 43 3 (2008) 170-178 {A}
81. Katzberg R.W., and Barrett B.J. Risk of iodinated contrast material-induced nephropathy with intravenous administration. Radiology 243 3 (2007) 622-628
82. Morcos S.K., Thomsen H.S., Webb J.A., et al. Dialysis and contrast media. Eur Radiol 12 12 (2002) 3026-3030